Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238353 | 0.89 | HCAR2 (0.32) | GSTP1HCAR2 | |
| SCHEMBL11211634 | 0.83 | GSTP1 (0.45) | GSTP1TP53HIF1AMAPTGRIA1 | |
| SCHEMBL743966 | 0.77 | — | — | |
| SCHEMBL6901471 | 0.75 | GSTP1 (0.33) | GSTP1 | |
| SCHEMBL1237584 | 0.73 | GSTP1 (0.46) | GSTP1TP53HIF1AMAPT | |
| SCHEMBL21633992 | 0.73 | GSTP1 (0.46) | GSTP1TP53HIF1AMAPTCYP3A4 | |
| SCHEMBL6902175 | 0.72 | GSTP1 (0.31) | GSTP1 | |
| SCHEMBL13715115 | 0.71 | GSTP1 (0.50) | GSTP1TP53MAPTALOX15 | |
| SCHEMBL6902367 | 0.71 | PTPN1 (0.34) | GSTP1MAPT | |
| SCHEMBL1238429 | 0.70 | GSTP1 (0.44) | GSTP1TP53HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409486-A1 | COMPOUND PRODUCING METHOD INCLUDING STEP OF ISOMERIZING ALPHA, BETA-UNSATURATED KETONE | KAO CORPORATION (JP) | 2024-12-12 | — | — | US | disclosed |
| CN-118103345-A | Method for producing compound comprising isomerization step of alpha, beta-unsaturated ketone | 花王株式会社 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023063030-A1 | COMPOUND PRODUCING METHOD INCLUDING STEP FOR ISOMERIZING α,β-UNSATURATED KETONE | 花王株式会社 | 2023-04-20 | — | — | WO | disclosed |
| EP-2266943-B1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | KAO CORP (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8394994-B2 | Method for producing of 2-alkyl-2-cycloalken-1-one | KAO CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110034722-A1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | KAO CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2266943-A1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | Kao Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409486-A1 | COMPOUND PRODUCING METHOD INCLUDING STEP OF ISOMERIZING ALPHA, BETA-UNSATURATED KETONE | CBR1, AKR1B1, AKR1C1 | GSTP1 864/4885TP53 3436/4885HIF1A 255/4885 |
| US-20110034722-A1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | PAOX, CYP1A1, ADH1A | GSTP1 3165/4885TP53 677/4885HIF1A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.